CD158f1/2 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-CD158f1/2 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityCD158f1/2
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatimmunogen affinity purified
Size0.03 mL, 0.1 mL, 0.2 mL
Concentration1 mg/ml
ApplicationsImmunohistochemistry (IHC) Paraffin, ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe antibody detects endogenous levels of CD158f1/2. Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13. within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several framework genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory sig
ImmunogenImmunogen: Synthesized peptide derived from part region of human CD158f1/2 protein at amino acid sequence of 31-80
Other Names[Rabbit CD158f1/2; Killer cell immunoglobulin-like receptor 2DL5A; KIR2DL5A; CD158f1; CD158F, CD158F1, KIR2DL5]
Gene, Accession #[CD158f1/2], Gene ID: 57292, NCBI: Q8N109.1, UniProt: Q8N109
Catalog #MBS9708622
Price$130, $220, $325
Order / More InfoCD158f1/2 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.